Technical Analysis for BEAM - Beam Therapeutics Inc.

Grade Last Price % Change Price Change
D 25.46 -5.46% -1.47
BEAM closed down 5.46 percent on Thursday, July 18, 2024, on 1.37 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Aug 6
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
200 DMA Support Bullish -5.46%
Upper Bollinger Band Walk Strength -5.46%
Overbought Stochastic Strength -5.46%
Upper Bollinger Band Touch Strength -5.46%
Gapped Down Weakness -5.46%
Crossed Above 200 DMA Bullish -6.71%

   Recent Intraday Alerts

Alert Time
Down 1 ATR about 17 hours ago
Down 5% about 18 hours ago
Down 3% about 21 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 2 % about 22 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder

Is BEAM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 49.5
52 Week Low 16.95
Average Volume 1,280,410
200-Day Moving Average 26.67
50-Day Moving Average 24.20
20-Day Moving Average 24.46
10-Day Moving Average 25.28
Average True Range 1.47
RSI (14) 53.27
ADX 15.52
+DI 31.41
-DI 21.35
Chandelier Exit (Long, 3 ATRs) 23.20
Chandelier Exit (Short, 3 ATRs) 26.67
Upper Bollinger Bands 27.28
Lower Bollinger Band 21.64
Percent B (%b) 0.68
BandWidth 23.04
MACD Line 0.57
MACD Signal Line 0.27
MACD Histogram 0.3
Fundamentals Value
Market Cap 2.08 Billion
Num Shares 81.5 Million
EPS -4.17
Price-to-Earnings (P/E) Ratio -6.11
Price-to-Sales 29.03
Price-to-Book 3.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.55
Resistance 3 (R3) 28.88 28.17 28.04
Resistance 2 (R2) 28.17 27.39 28.01 27.86
Resistance 1 (R1) 26.82 26.90 26.47 26.49 27.69
Pivot Point 26.11 26.11 25.94 25.95 26.11
Support 1 (S1) 24.76 25.33 24.41 24.43 23.23
Support 2 (S2) 24.05 24.84 23.89 23.06
Support 3 (S3) 22.70 24.05 22.89
Support 4 (S4) 22.37